In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. [PDF]
J Antimicrob ChemotherAbstract Background and objectives Mycobacterium abscessus has extensive innate and acquired antibiotic resistance resulting in limited antibiotic treatment options and poor clinical outcomes. Currently, the only β-lactam antibiotics with efficacy against M. abscessus are imipenem and cefoxitin.
Patterson-Fahy K +5 more
europepmc +5 more sources
Susceptibility toward cefiderocol and sulbactam-durlobactam in extensively drug-resistant <i>Acinetobacter baumannii</i> detected from ICU admission screening in Hanoi, Vietnam, 2023. [PDF]
Microbiol SpectrInfections due to carbapenem-resistant Acinetobacter baumannii (CRAB) pose significant clinical challenges due to limited treatment options. In this study, we investigated the molecular epidemiology, resistance profiles, and genomic characteristics of ...
Boutin S +15 more
europepmc +2 more sources
Evaluation of sulbactam/durlobactam activity and synergy against highly drug-resistant <i>Acinetobacter baumannii</i> strains. [PDF]
JAC Antimicrob ResistAbstract Background Acinetobacter baumannii is a bacterial pathogen frequently implicated in healthcare-associated infections, with limited effective treatment options due to widespread antibiotic resistance.
Halim J, Bouzo J, Carabetta VJ.
europepmc +3 more sources
Frontiers in MedicineMeningitis caused by Acinetobacter species is a rare complication of neurosurgical procedures, although it is associated with high morbidity and mortality.
Nicholas J Mercuro
exaly +3 more sources
Multidrug-Resistant Acinetobacter baumannii: Resistance Mechanisms, Emerging Therapies, and Prevention-A Narrative Review. [PDF]
Antibiotics (Basel)Acinetobacter baumannii is a leading intensive care unit (ICU) pathogen associated with high rates of carbapenem resistance and poor clinical outcomes.
Stoian IA +7 more
europepmc +2 more sources
Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations. [PDF]
Infect Drug ResistMilo Gatti,1,2 Federico Pea1,2 1Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 2Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ItalyCorrespondence ...
Gatti M, Pea F.
europepmc +2 more sources
Comparative <i>in vitro</i> activity of sulbactam with avibactam or durlobactam against carbapenem-resistant <i>Acinetobacter baumannii</i>. [PDF]
JAC Antimicrob ResistAbstract Objective To determine the in vitro activity of sulbactam in combination with avibactam or durlobactam with and without meropenem or imipenem against carbapenem-resistant Acinetobacter baumannii clinical isolates.
Dorazio AJ +5 more
europepmc +3 more sources
Successful Treatment of OXA-23 <i>Acinetobacter baumannii</i> Pneumonia with Sulbactam-Durlobactam in a Liver Transplant Recipient. [PDF]
Infect Drug ResistLiver transplant recipients face a higher risk of multidrug-resistant (MDR) infections because of preoperative comorbidities, extensive antibiotic use, immunosuppressive therapy, and prolonged mechanical ventilation. Carbapenem-resistant Acinetobacter baumannii (CRAB) remains one of the most challenging pathogens in this group.
Yin G +5 more
europepmc +3 more sources
Journal of Global Antimicrobial Resistance: Objectives: This study aimed to investigate sulbactam-durlobactam (SUL-DUR) susceptibility and molecular features of carbapenem-resistant Acinetobacter baumannii (CRAB) isolates from a Shenzhen teaching hospital. Methods: A retrospective study on CRAB
Hanlian Huang +7 more
doaj +3 more sources
Antibiotics Usage in Special Clinical Situations [PDF]
, 2023 Medicine and the treatment of infectious diseases are increasingly focused on patient-tailored diagnostics and therapy [...]
Di Bella, Stefano
core +1 more source